Another large cancer hospital is about to open!

Another large oncology hospital in the southwest region is about to open.

The author | Xiao Xiang

Source| Medical Community (ID: vistamed)

Recently, according to Jiupai News, Chongqing Global Cancer Hospital is under construction, and the reporter visited and found that the project has entered the stage of internal decoration and equipment installation, and the completion and commissioning are just around the corner.

According to public information, Chongqing Global Cancer Hospital is located in Wanzhou Economic and Technological Development Zone, Chongqing, and in March 2019, the hospital was officially approved by the Chongqing Municipal Health Commission and is a modern tertiary cancer specialty hospital. The total investment is 3 billion yuan, with a total area of 176.6 mu, a construction area of 280,000 square meters, and a total design bed of 1,700 beds. Among them, the first phase is planned for 410 beds, which is expected to be put into operation in May this year.

Enterprise investigation information shows that Chongqing Global Cancer Hospital was established in 2018, jointly invested and created by Chongqing Houjie Pharmaceutical Group and Beijing Global Medical Technology Co., Ltd. In June 2021, Beijing Global Medical withdrew from the hospital investment and changed to 20.7% of the shares held by its subsidiary Beijing Nains Technology Co., Ltd., Houjie Pharmaceutical Group held 74.6% of the shares to become the major shareholder, Chongqing Wanzhou Economic and Technological Development Group held 4.6% of the shares, and the tripartite joint investment and construction.

A number of listed companies have laid out tumor tracks

The tertiary cancer specialty hospital with a total planning of 1700 beds can be described as a big momentum. According to the medical community, with the continuous improvement of the survival rate of patients, tumors have gradually become chronic diseases, and the nature of hypertension and diabetes has gradually converged, and the market for tumor diseases is huge. In this context, a number of listed companies have targeted the tumor track and entered this field in large numbers.

In October 2021, Yibai Pharmaceutical, a listed company, announced that the company intends to acquire 70% of the equity of Deyang Cancer Hospital Co., Ltd. held by Foji Medical Management, Foming Medical Management and Foxiang Medical Management for 336 million yuan. After the completion of the acquisition, Deyang Cancer Hospital will become a holding subsidiary of Yibai Pharmaceutical. According to the announcement, oncology medical services are the core business of Yibai Pharmaceutical Medical Services, and the main business of Deyang Cancer Hospital is tumor-related specialty medical services, which belongs to the expansion of the company's medical service business segment.

In June and October 2021, yonghe zhikong, an A-share listed company, issued two consecutive announcements on the progress of major asset restructuring and related party transactions, announcing its withdrawal from the fluid intelligent control business and focusing on the medical and health industry, and is expected to invest no less than 430 million yuan in transaction funds, all of which will be invested in the medical industry.

In response to investors' questions, Yonghe Zhikong said that the company will position itself as "pure tumor precision radiation therapy" and build a chain of specialized hospitals with precision radiation therapy for tumors as the core of service. Previously, Yonghe Zhikong has acquired Dazhou Medical Cancer Hospital and Kunming Medical Cancer Hospital, and also participated in Xi'an Medical Cancer Hospital and newly established Chongqing Huapu Cancer Hospital.

Another Haier listed company, Yingkang Life (300143. SZ), also announced the acquisition of 100% equity of Suzhou Guangci Cancer Hospital Co., Ltd. in May 2021, with a transaction consideration of 631 million yuan. It is reported that Suzhou Guangci Hospital (Guangci Hospital of the First Affiliated Hospital of Soochow University) has been operating for more than 15 years and is a second-level comprehensive medical institution featuring tumor treatment, with 320 beds and about 500 employees.

The field of oncology has received attention from the capital market, and it can be said that it is inseparable from the listing of the oncology medical service chain Hygia. According to the medical community, in June 2020, the oncology medical service chain Haijiya went public in Hong Kong and was warmly welcomed by the capital market. Although there have been some recent shocks, The current market value of Hygia is still nearly 15 billion yuan. It is reported that the company's main business includes self-operated cancer hospitals, third-party radiotherapy center services and hospital trusteeship, and it has 10 hospitals with oncology as the core, of which 7 are self-owned hospitals and 3 are managed hospitals.

The market for oncology medical services is huge

According to Frost & Sullivan data, it is expected that the scale of the radiation therapy market in mainland cancer hospitals will grow to 80.9 billion yuan in 2025, and from 2020 to 2025, the size of China's oncology medical service market is expected to increase to 700.3 billion yuan with a compound annual growth rate of 11.54%.

Professor Ding Gang, founder of Xuanhe Medical-Ding Gang Oncology Doctor Group and director of the Cancer Center of Shanghai International Medical Center, said that the incidence of tumors in China is not optimistic, not only the absolute number of patients is huge, but also the mortality rate is also in the top two. Although with the advancement of medical technology, the five-year survival rate of cancer patients has reached 40% in ten years, but it is still a huge gap compared with European and American countries. According to reports, as early as the 50s, the five-year survival rate of tumor patients in Europe and the United States has reached 49%, and now it is close to 70%.

Industry insiders said that in recent years, in the construction of hierarchical diagnosis and treatment of strong grass-roots level, as a high incidence, chronic diseases, major diseases of tumor medical services have become a short board that is difficult for grass-roots public hospitals to make up in the short term, so it also provides a blue ocean market for market-oriented medical treatment, in the next decade, there will be more capital and doctor teams to enter the layout of tumor medical services, or there will be more listed companies with tumor medical service business as the main business, and will accelerate the layout in the market. (This article is published by "Seeing the Medical Community", reprinted with permission, and the author and source are indicated at the beginning of the article.) ）

END

The 2022 National Hospital Operation Conference is coming!

From "large-scale construction" to "fine operation", how to establish a modern hospital management system? How to achieve refined, high-quality and leapfrog development of medical institutions through benign operation? How to build a market-recognized brand ?.... On May 28-29, the 2022 National Hospital Operation Conference sponsored by the 2022 Shanghai Medical Fair Expert Committee, the Institute of Social Medical Institutions of Shanghai Jiaotong University, and the medical media will be held in Shanghai.